Trajectory and mortality of Preserved Ratio Impaired Spirometry: the Rotterdam Study.
Preserved Ratio Impaired Spirometry (PRISm) is a heterogeneous condition but its course and disease progression remain to be elucidated. We aimed to examine its prevalence, trajectories and prognosis in the general population.In the Rotterdam Study (population-based prospective cohort) we examined prevalence, trajectories and prognosis of subjects with normal spirometry (controls; FEV1/FVC≥0.7, FEV1≥80%), PRISm (FEV1/FVC≥0.7, FEV1<80%), and COPD (FEV1/FVC<0.7) at two study visits. Hazard ratios (HR 95%CI) for mortality (until 30/12/2018) were adjusted for age, sex, BMI, current smoking and pack-years.Of 5487 subjects (age 69.1±8.9; 7.1% PRISm), 1603 were re-examined after 4.5 years. Of PRISm subjects with re-examination, 15.7% transitioned to normal spirometry and 49.4% to COPD. Lung function decline (mL·year-1) was highest in subjects with incident PRISm (FEV1: -92.8[-131.9,-65.8]; FVC: -93.3[-159.8,-49.1]), but similar in persistent PRISm (FEV1: -30.2[-67.9,-7.5]; FVC: -20.1[-47.7,+21.7]) and persistent controls (FEV1: -39.6[-64.3,-12.7]; FVC: -20.0[-55.4,+18.8]). Of 5459 subjects with informed consent for follow-up, 692 (12.7%) died during 9.3 years (maximum) follow-up: 10.3% of controls, 18.7% of PRISm subjects and 20.8% of COPD subjects. Relative to controls, subjects with PRISm and COPD GOLD2-4 had increased all-cause and cardiovascular mortality (PRISm: HR 1.6[1.2, 2.0] and 2.8[1.5, 5.1]; COPD GOLD2-4: HR 1.7[1.4, 2.1] and 2.1[1.2, 3.6]). Mortality <1 year was highest in PRISm, often having cardiovascular comorbidity (heart failure or coronary heart disease; 70.0%).PRISm is associated with increased mortality and this population encompasses at least three distinct subsets: one that develops COPD during follow-up, a second with high cardiovascular burden and early mortality, and a third with persistent PRISm and normal age-related lung function decline.